The double-edged sword of AMPK signaling in cancer and its therapeutic implications

Archives of Pharmacal Research

Volumn 38, Issue 3, 2015, Pages 346-357

  Jeon, Sang Min ^a   Hay, Nissim ^b  

^a Ajou University   (South Korea)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

ACC; AMPK; Biguanides; CAMKK2; Cancer; Fatty acids; LKB1; Metabolic stress; Mitochondria; mTORC1; NADPH; ROS

Indexed keywords

5' HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; BIGUANIDE DERIVATIVE; CALMODULIN DEPENDENT KINASE KINASE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN KINASE LKB1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

CELL HYPOXIA; HUMAN; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; CELL SURVIVAL; DRUG RESISTANCE; HOMEOSTASIS; METABOLISM; NEOPLASMS; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HOMEOSTASIS; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EID: 84923927635     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-015-0549-z     Document Type: Review

References (85)

1. Appleyard, M.V., K.E. Murray, P.J. Coates, S. Wullschleger, S.E. Bray, N.M. Kernohan, S. Fleming, D.R. Alessi, and A.M. Thompson. 2012. Phenformin as prophylaxis and therapy in breast cancer xenografts. British Journal of Cancer 106: 1117-1122.
2. Auciello, F.R., F.A. Ross, N. Ikematsu, and D.G. Hardie. 2014. Oxidative stress activates AMPK in cultured cells primarily by increasing cellular AMP and/or ADP. FEBS Letters 588: 3361-3366.
3. Bardeesy, N., M. Sinha, A.F. Hezel, S. Signoretti, N.A. Hathaway, N.E. Sharpless, M. Loda, D.R. Carrasco, and R.A. Depinho. 2002. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419: 162-167.
4. Borgdorff, V., U. Rix, G.E. Winter, M. Gridling, A.C. Muller, F.P. Breitwieser, C. Wagner, J. Colinge, K.L. Bennett, G. Superti-Furga, and S.N. Wagner. 2014. A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. Oncogene 33: 2531-2539.
5. Buzzai, M., R.G. Jones, R.K. Amaravadi, J.J. Lum, R.J. Deberardinis, F. Zhao, B. Viollet, and C.B. Thompson. 2007. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Research 67: 6745-6752.
6. Cardaci, S., G. Filomeni, and M.R. Ciriolo. 2012. Redox implications of AMPK-mediated signal transduction beyond energetic clues. Journal of Cell Science 125: 2115-2125.
7. Carling, D., V.A. Zammit, and D.G. Hardie. 1987. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Letters 223: 217-222.
8. Carretero, J., T. Shimamura, K. Rikova, A.L. Jackson, M.D. Wilkerson, C.L. Borgman, M.S. Buttarazzi, B.A. Sanofsky, K.L. Mcnamara, K.A. Brandstetter, Z.E. Walton, T.L. Gu, J.C. Silva, K. Crosby, G.I. Shapiro, S.M. Maira, H. Ji, D.H. Castrillon, C.F. Kim, C. Garcia-Echeverria, N. Bardeesy, N.E. Sharpless, N.D. Hayes, W.Y. Kim, J.A. Engelman, and K.K. Wong. 2010. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17: 547-559.
9. Cheng, H., P. Liu, F. Zhang, E. Xu, L. Symonds, C.E. Ohlson, R.T. Bronson, S.M. Maira, E. Di Tomaso, J. Li, A.P. Myers, L.C. Cantley, G.B. Mills, and J.J. Zhao. 2014. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Research 74: 15-23.
10. Choi, S.L., S.J. Kim, K.T. Lee, J. Kim, J. Mu, M.J. Birnbaum, S. Soo Kim, and J. Ha. 2001. The regulation of AMP-activated protein kinase by H(2)O(2). Biochemical and biophysical research communications 287: 92-97.
11. Contreras, C.M., E.A. Akbay, T.D. Gallardo, J.M. Haynie, S. Sharma, O. Tagao, N. Bardeesy, M. Takahashi, J. Settleman, K.K. Wong, and D.H. Castrillon. 2010. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Disease models & mechanisms 3: 181-193.
12. Contreras, C.M., S. Gurumurthy, J.M. Haynie, L.J. Shirley, E.A. Akbay, S.N. Wingo, J.O. Schorge, R.R. Broaddus, K.K. Wong, N. Bardeesy, and D.H. Castrillon. 2008. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Research 68: 759-766.
13. Corradetti, M.N., K. Inoki, N. Bardeesy, R.A. Depinho, and K.L. Guan. 2004. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes & Development 18: 1533-1538.
14. Davies, S.P., N.R. Helps, P.T. Cohen, and D.G. Hardie. 1995. 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Letters 377: 421-425.
15. Decensi, A., M. Puntoni, P. Goodwin, M. Cazzaniga, A. Gennari, B. Bonanni, and S. Gandini. 2010. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer prevention research 3: 1451-1461.
16. Dupuy, F., T. Griss, J. Blagih, G. Bridon, D. Avizonis, C. Ling, Z. Dong, D.R. Siwak, M.G. Annis, G.B. Mills, W.J. Muller, P.M. Siegel, and R.G. Jones. 2013. LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. Cancer & metabolism 1: 18.
17. El-Masry, O.S., B.L. Brown, and P.R. Dobson. 2012. Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds. Oncology letters 3: 224-228.
18. Emerling, B.M., F. Weinberg, C. Snyder, Z. Burgess, G.M. Mutlu, B. Viollet, G.R. Budinger, and N.S. Chandel. 2009. Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio. Free Radical Biology and Medicine 46: 1386-1391.
19. Evans, J.M., L.A. Donnelly, A.M. Emslie-Smith, D.R. Alessi, and A.D. Morris. 2005. Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305.
20. Faubert, B., G. Boily, S. Izreig, T. Griss, B. Samborska, Z. Dong, F. Dupuy, C. Chambers, B.J. Fuerth, B. Viollet, O.A. Mamer, D. Avizonis, R.J. Deberardinis, P.M. Siegel, and R.G. Jones. 2013. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metabolism 17: 113-124.
21. Faubert, B., E.E. Vincent, T. Griss, B. Samborska, S. Izreig, R.U. Svensson, O.A. Mamer, D. Avizonis, D.B. Shackelford, R.J. Shaw, and R.G. Jones. 2014a. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1alpha. Proceedings of the National Academy of Sciences of the United States of America 111: 2554-2559.
22. Faubert, B., E.E. Vincent, M.C. Poffenberger, and R.G. Jones, 2014b. The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator. Cancer letters 356(2): 165-70. doi: 10.1016/j.canlet.2014.01.018.
23. Fernandez, M.R., M.D. Henry, and R.E. Lewis. 2012. Kinase suppressor of Ras 2 (KSR2) regulates tumor cell transformation via AMPK. Molecular and Cellular Biology 32: 3718-3731.
24. Frigo, D.E., M.K. Howe, B.M. Wittmann, A.M. Brunner, I. Cushman, Q. Wang, M. Brown, A.R. Means, and D.P. Mcdonnell. 2011. CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. Cancer Research 71: 528-537.
25. Fung, C., R. Lock, S. Gao, E. Salas, and J. Debnath. 2008. Induction of autophagy during extracellular matrix detachment promotes cell survival. Molecular Biology of the Cell 19: 797-806.
26. Godlewski, J., M.O. Nowicki, A. Bronisz, G. Nuovo, J. Palatini, M. De Lay, J. Van Brocklyn, M.C. Ostrowski, E.A. Chiocca, and S.E. Lawler. 2010. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Molecular Cell 37: 620-632.
27. Goodwin, J.M., R.U. Svensson, H.J. Lou, M.M. Winslow, B.E. Turk, and R.J. Shaw. 2014. An AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls Snail1 and metastatic potential. Molecular Cell 55: 436-450.
28. Gowans, G.J., S.A. Hawley, F.A. Ross, and D.G. Hardie. 2013. AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metabolism 18: 556-566.
29. Hadad, S.M., S. Fleming, and A.M. Thompson. 2008. Targeting AMPK: a new therapeutic opportunity in breast cancer. Critical reviews in oncology/hematology 67: 1-7.
30. Hardie, D.G., and D.R. Alessi. 2013. LKB1 and AMPK and the cancer-metabolism link - ten years after. BMC Biology 11: 36.
31. Hardie, D.G., F.A. Ross, and S.A. Hawley. 2012. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature Reviews Molecular Cell Biology 13: 251-262.
32. Hawley, S.A., J. Boudeau, J.L. Reid, K.J. Mustard, L. Udd, T.P. Makela, D.R. Alessi, and D.G. Hardie. 2003. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. Journal of biology 2: 28.
33. Hawley, S.A., D.A. Pan, K.J. Mustard, L. Ross, J. Bain, A.M. Edelman, B.G. Frenguelli, and D.G. Hardie. 2005. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metabolism 2: 9-19.
34. Hawley, S.A., F.A. Ross, C. Chevtzoff, K.A. Green, A. Evans, S. Fogarty, M.C. Towler, L.J. Brown, O.A. Ogunbayo, A.M. Evans, and D.G. Hardie. 2010. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metabolism 11: 554-565.
35. Hemminki, A., D. Markie, I. Tomlinson, E. Avizienyte, S. Roth, A. Loukola, G. Bignell, W. Warren, M. Aminoff, P. Hoglund, H. Jarvinen, P. Kristo, K. Pelin, M. Ridanpaa, R. Salovaara, T. Toro, W. Bodmer, S. Olschwang, A.S. Olsen, M.R. Stratton, A. De La Chapelle, and L.A. Aaltonen. 1998. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391: 184-187.
36. Hindupur, S.K., S.A. Balaji, M. Saxena, S. Pandey, G. Sravan, N. Heda, M. Kumar, G. Mukherjee, D. Dey, and A. Rangarajan. 2014. Identification of a novel AMPK-PEA15 axis in the anoikis-resistant growth of mammary cells. Breast cancer research: BCR 16: 420.
37. Hirsch, H.A., D. Iliopoulos, P.N. Tsichlis, and K. Struhl. 2009. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Research 69: 7507-7511.
38. Honjo, S., J.A. Ajani, A.W. Scott, Q. Chen, H.D. Skinner, J. Stroehlein, R.L. Johnson, and S. Song. 2014. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. International Journal of Oncology 45: 567-574.
39. Inoki, K., T. Zhu, and K.L. Guan. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
40. Jang, T., J.M. Calaoagan, E. Kwon, S. Samuelsson, L. Recht, and K.R. Laderoute. 2011. 5′-AMP-activated protein kinase activity is elevated early during primary brain tumor development in the rat. International journal of cancer. Journal international du cancer 128: 2230-2239.
41. Janzer, A., N.J. German, K.N. Gonzalez-Herrera, J.M. Asara, M.C. Haigis, and K. Struhl. 2014. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proceedings of the National Academy of Sciences of the United States of America 111: 10574-10579.
42. Jeon, S.M., N.S. Chandel, and N. Hay. 2012. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485: 661-665.
43. Jeon, S.M., and N. Hay. 2012. The dark face of AMPK as an essential tumor promoter. Cellular logistics 2: 197-202.
44. Ji, H., M.R. Ramsey, D.N. Hayes, C. Fan, K. Mcnamara, P. Kozlowski, C. Torrice, M.C. Wu, T. Shimamura, S.A. Perera, M.C. Liang, D. Cai, G.N. Naumov, L. Bao, C.M. Contreras, D. Li, L. Chen, J. Krishnamurthy, J. Koivunen, L.R. Chirieac, R.F. Padera, R.T. Bronson, N.I. Lindeman, D.C. Christiani, X. Lin, G.I. Shapiro, P.A. Janne, B.E. Johnson, M. Meyerson, D.J. Kwiatkowski, D.H. Castrillon, N. Bardeesy, N.E. Sharpless, and K.K. Wong. 2007. LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810.
45. Kato, K., T. Ogura, A. Kishimoto, Y. Minegishi, N. Nakajima, M. Miyazaki, and H. Esumi. 2002. Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene 21: 6082-6090.
46. Kim, I., and Y.Y. He. 2013. Targeting the AMP-activated protein kinase for cancer prevention and therapy. Frontiers in oncology 3: 175.
47. Laderoute, K.R., K. Amin, J.M. Calaoagan, M. Knapp, T. Le, J. Orduna, M. Foretz, and B. Viollet. 2006. 5′-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Molecular and Cellular Biology 26: 5336-5347.
48. Laderoute, K.R., J.M. Calaoagan, W.R. Chao, D. Dinh, N. Denko, S. Duellman, J. Kalra, X. Liu, I. Papandreou, L. Sambucetti, and L.G. Boros. 2014. 5′-AMP-activated protein kinase (AMPK) supports the growth of aggressive experimental human breast cancer tumors. The Journal of biological chemistry 289: 22850-22864.
49. Laderoute, K.R., J.M. Calaoagan, P.B. Madrid, A.E. Klon, and P.J. Ehrlich. 2010. SU11248 (sunitinib) directly inhibits the activity of mammalian 5′-AMP-activated protein kinase (AMPK). Cancer Biology & Therapy 10: 68-76.
50. Liang, J., and G.B. Mills. 2013. AMPK: a contextual oncogene or tumor suppressor? Cancer Research 73: 2929-2935.
51. Liu, L., J. Ulbrich, J. Muller, T. Wustefeld, L. Aeberhard, T.R. Kress, N. Muthalagu, L. Rycak, R. Rudalska, R. Moll, S. Kempa, L. Zender, M. Eilers, and D.J. Murphy. 2012. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 483: 608-612.
52. Liu, X., R.R. Chhipa, S. Pooya, M. Wortman, S. Yachyshin, L.M. Chow, A. Kumar, X. Zhou, Y. Sun, B. Quinn, C. Mcpherson, R.E. Warnick, A. Kendler, S. Giri, J. Poels, K. Norga, B. Viollet, G.A. Grabowski, and B. Dasgupta. 2014. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proceedings of the National Academy of Sciences of the United States of America 111: E435-E444.
53. Lonardo, E., M. Cioffi, P. Sancho, Y. Sanchez-Ripoll, S.M. Trabulo, J. Dorado, A. Balic, M. Hidalgo, and C. Heeschen. 2013. Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS ONE 8: e76518.
54. Massie, C.E., A. Lynch, A. Ramos-Montoya, J. Boren, R. Stark, L. Fazli, A. Warren, H. Scott, B. Madhu, N. Sharma, H. Bon, V. Zecchini, D.M. Smith, G.M. Denicola, N. Mathews, M. Osborne, J. Hadfield, S. Macarthur, B. Adryan, S.K. Lyons, K.M. Brindle, J. Griffiths, M.E. Gleave, P.S. Rennie, D.E. Neal, and I.G. Mills. 2011. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. The EMBO journal 30: 2719-2733.
55. Mizrachy-Schwartz, S., N. Cohen, S. Klein, N. Kravchenko-Balasha, and A. Levitzki. 2011. Up-regulation of AMP-activated protein kinase in cancer cell lines is mediated through c-Src activation. The Journal of biological chemistry 286: 15268-15277.
56. Mohseni, M., J. Sun, A. Lau, S. Curtis, J. Goldsmith, V.L. Fox, C. Wei, M. Frazier, O. Samson, K.K. Wong, C. Kim, and F.D. Camargo. 2014. A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nature Cell Biology 16: 108-117.
57. Mungai, P.T., G.B. Waypa, A. Jairaman, M. Prakriya, D. Dokic, M.K. Ball, and P.T. Schumacker. 2011. Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. Molecular and Cellular Biology 31: 3531-3545.
58. Nair, V., S. Sreevalsan, R. Basha, M. Abdelrahim, A. Abudayyeh, Hoffman.A. Rodrigues, and S. Safe. 2014. Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. The Journal of biological chemistry 289: 27692-27701.
59. Ng, T.L., G. Leprivier, M.D. Robertson, C. Chow, M.J. Martin, K.R. Laderoute, E. Davicioni, T.J. Triche, and P.H. Sorensen. 2012. The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis. Cell Death and Differentiation 19: 501-510.
60. Phoenix, K.N., C.V. Devarakonda, M.M. Fox, L.E. Stevens, and K.P. Claffey. 2012. AMPKalpha2 suppresses murine embryonic fibroblast transformation and tumorigenesis. Genes and cancer 3: 51-62.
61. Pollak, M. 2013. Potential applications for biguanides in oncology. The Journal of Clinical Investigation 123: 3693-3700.
62. Possik, E., Z. Jalali, Y. Nouet, M. Yan, M.C. Gingras, K. Schmeisser, L. Panaite, F. Dupuy, D. Kharitidi, L. Chotard, R.G. Jones, D.H. Hall, and A. Pause. 2014. Folliculin regulates ampk-dependent autophagy and metabolic stress survival. PLoS Genetics 10: e1004273.
63. Rios, M., M. Foretz, B. Viollet, A. Prieto, M. Fraga, J.A. Costoya, and R. Senaris. 2013. AMPK activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors. Cancer Research 73: 2628-2638.
64. Ros, S., C.R. Santos, S. Moco, F. Baenke, G. Kelly, M. Howell, N. Zamboni, and A. Schulze. 2012. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer discovery 2: 328-343.
65. Rosilio, C., N. Lounnas, M. Nebout, V. Imbert, T. Hagenbeek, H. Spits, V. Asnafi, R. Pontier-Bres, J. Reverso, J.F. Michiels, I.B. Sahra, F. Bost, and J.F. Peyron. 2013. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells. Cancer Letters 336: 114-126.
66. Sahra, I.B., C. Regazzetti, G. Robert, K. Laurent, Y. Le Marchand-Brustel, P. Auberger, J.F. Tanti, S. Giorgetti-Peraldi, and F. Bost. 2011. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Research 71(13): 4366-4372.
67. Schafer, Z.T., A.R. Grassian, L. Song, Z. Jiang, Z. Gerhart-Hines, H.Y. Irie, S. Gao, P. Puigserver, and J.S. Brugge. 2009. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461: 109-113.
68. Shackelford, D.B., E. Abt, L. Gerken, D.S. Vasquez, A. Seki, M. Leblanc, L. Wei, M.C. Fishbein, J. Czernin, P.S. Mischel, and R.J. Shaw. 2013. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 23: 143-158.
69. Shackelford, D.B., and R.J. Shaw. 2009. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nature Reviews Cancer 9: 563-575.
70. Shank, J.J., K. Yang, J. Ghannam, L. Cabrera, C.J. Johnston, R.K. Reynolds, and R.J. Buckanovich. 2012. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecologic Oncology 127: 390-397.
71. She, C., L.Q. Zhu, Y.F. Zhen, X.D. Wang, and Q.R. Dong. 2014. Activation of AMPK protects against hydrogen peroxide-induced osteoblast apoptosis through autophagy induction and NADPH maintenance: new implications for osteonecrosis treatment? Cellular Signalling 26: 1-8.
72. Sinnett, S.E., and J.E. Brenman. 2014. Past strategies and future directions for identifying AMP-activated protein kinase (AMPK) modulators. Pharmacology & Therapeutics 143: 111-118.
73. Song, C.W., H. Lee, R.P. Dings, B. Williams, J. Powers, T.D. Santos, B.H. Choi, and H.J. Park. 2012. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Scientific reports 2: 362.
74. Steinberg, G.R., and B.E. Kemp. 2009. AMPK in health and disease. Physiological Reviews 89: 1025-1078.
75. Tennakoon, J.B., Y. Shi, J.J. Han, E. Tsouko, M.A. White, A.R. Burns, A. Zhang, X. Xia, O.R. Ilkayeva, L. Xin, M.M. Ittmann, F.G. Rick, A.V. Schally, and D.E. Frigo. 2013. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1alpha-mediated metabolic switch. Oncogene. 33(45): 5251-5261.
76. Vazquez-Martin, A., C. Oliveras-Ferraros, S. Del Barco, B. Martin-Castillo, and J.A. Menendez. 2011. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Research and Treatment 126: 355-364.
77. Viale, A., P. Pettazzoni, C.A. Lyssiotis, H. Ying, N. Sanchez, M. Marchesini, A. Carugo, T. Green, S. Seth, V. Giuliani, M. Kost-Alimova, F. Muller, S. Colla, L. Nezi, G. Genovese, A.K. Deem, A. Kapoor, W. Yao, E. Brunetto, Y. Kang, M. Yuan, J.M. Asara, Y.A. Wang, T.P. Heffernan, A.C. Kimmelman, H. Wang, J.B. Fleming, L.C. Cantley, R.A. Depinho, and G.F. Draetta. 2014. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514(7524): 628-632.
78. Vincent, E. E., P.P. Coelho, J. Blagih, T. Griss, B. Viollet, and R.G. Jones, 2014. Differential effects of AMPK agonists on cell growth and metabolism. Oncogene. doi: 10.1038/onc.2014.301.
79. Woods, A., K. Dickerson, R. Heath, S.P. Hong, M. Momcilovic, S.R. Johnstone, M. Carlson, and D. Carling. 2005. Ca2 +/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metabolism 2: 21-33.
80. Woods, A., S.R. Johnstone, K. Dickerson, F.C. Leiper, L.G. Fryer, D. Neumann, U. Schlattner, T. Wallimann, M. Carlson, and D. Carling. 2003. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Current biology: CB 13: 2004-2008.
81. Xu, C., C.M. Fillmore, S. Koyama, H. Wu, Y. Zhao, Z. Chen, G.S. Herter-Sprie, E.A. Akbay, J.H. Tchaicha, A. Altabef, J.B. Reibel, Z. Walton, H. Ji, H. Watanabe, P.A. Janne, D.H. Castrillon, A.K. Rustgi, A.J. Bass, G.J. Freeman, R.F. Padera, G. Dranoff, P.S. Hammerman, C.F. Kim, and K.K. Wong. 2014. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 25: 590-604.
82. Yan, M., M.C. Gingras, E.A. Dunlop, Y. Nouet, F. Dupuy, Z. Jalali, E. Possik, B.J. Coull, D. Kharitidi, A.B. Dydensborg, B. Faubert, M. Kamps, S. Sabourin, R.S. Preston, D.M. Davies, T. Roughead, L. Chotard, M.A. Van Steensel, R. Jones, A.R. Tee, and A. Pause. 2014. The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation. The Journal of Clinical Investigation 124: 2640-2650.
83. Zhang, Y.L., H. Guo, C.S. Zhang, S.Y. Lin, Z. Yin, Y. Peng, H. Luo, Y. Shi, G. Lian, C. Zhang, M. Li, Z. Ye, J. Ye, J. Han, P. Li, J.W. Wu, and S.C. Lin. 2013. AMP as a low-energy charge signal autonomously initiates assembly of AXIN-AMPK-LKB1 complex for AMPK activation. Cell Metabolism 18: 546-555.
84. Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M.F. Hirshman, L.J. Goodyear, and D.E. Moller. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. The Journal of Clinical Investigation 108: 1167-1174.
85. Zmijewski, J.W., S. Banerjee, H. Bae, A. Friggeri, E.R. Lazarowski, and E. Abraham. 2010. Exposure to hydrogen peroxide induces oxidation and activation of AMP-activated protein kinase. The Journal of biological chemistry 285: 33154-33164.